Stereotaxis Invited by Africa Heart Rhythm Association to Present its Innovative Robotic Solution to Expand High-Quality Therapy in Underserved Regions of Africa

Written by Customer Service on May 15, 2024. Posted in Public Companies.

ST. LOUIS, May 15, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has been invited to present at HRS Africa Summit 2024, scheduled to take place during Heart Rhythm Society Scientific Sessions this week in Boston, Massachusetts. Stereotaxis will present an innovative proposal leveraging advanced robotic technology and telerobotic presence to sustainably offer high-quality cardiac ablation therapy in underserved regions of Africa. Africa is the second most populous and fastest growing continent, and yet has a nearly non-existent infrastructure of electrophysiology (EP) labs to provide cardiac ablation therapy. Cardiac ablation is a common minimally invasive procedure to treat arrhythmias – abnormal heart...

CloudMD Announces Go-Private Transaction with CPS Capital

Written by Customer Service on May 15, 2024. Posted in Public Companies.

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) — CloudMD Software & Services Inc. (TSXV: DOC, Frankfurt: 6PH) (the “Company” or “CloudMD”), an innovative health services company transforming the delivery of care, and CPS Capital (“CPS Capital”), an entrepreneurial investment firm partnering with businesses and teams to realize their growth goals, are pleased to announce that they have entered into an arrangement agreement (the “Arrangement Agreement”) pursuant to which CPS Capital (through an affiliate) (the “Purchaser”) has agreed to acquire all of the outstanding common shares (the “Shares”) of CloudMD for cash consideration of C$0.04 per Share (the “Transaction”). The Transaction is the culmination of a strategic and liquidity review that the Special Committee (as defined below) has been engaged in since July 2023, with the assistance...

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

Written by Customer Service on May 15, 2024. Posted in Public Companies.

SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the last patient in the Company’s Karisma-Endoxifen clinical trial received their final dose of study medication. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The Karisma-Endoxifen study, which fully enrolled in November 2023, is a 240-person Phase 2 clinical trial investigating (Z)-endoxifen in premenopausal women with measurable mammographic breast density (MBD). Participants were randomized to placebo, 1 mg, and 2 mg daily doses of (Z)-endoxifen and treated for six months, over the course of which mammograms are conducted to measure reduction in MBD. Medication-induced MBD...

Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss

Written by Customer Service on May 15, 2024. Posted in Public Companies.

MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced Steven B. Heymsfield, M.D., a Professor and the Director of the Body Composition-Metabolism Laboratory at the Pennington Biomedical Research Center in Baton Rouge, Louisiana, as the Principal Investigator for the Company’s Phase 2b clinical trial of enobosarm to preserve muscle while augmenting fat loss in patients receiving a GLP-1 RA for weight loss. Dr. Heymsfield is a leading authority on body composition assessment and his research focuses primarily on human obesity, including energy balance regulation, weight loss treatments, co-morbidity...

ERES REIT Declares May 2024 Monthly Distribution

Written by Customer Service on May 15, 2024. Posted in Public Companies.

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) — European Residential Real Estate Investment Trust (TSX: ERE.UN, “ERES”) is pleased to announce that the trustees of ERES have declared the May 2024 monthly cash distribution of €0.01 per Unit and Class B LP Unit (the “May Distribution”), being equivalent to €0.12 per Unit annualized. The distribution will be payable to holders of the Units and Class B LP Units (the “Unitholders”) of record on May 31, 2024, with payment on June 17, 2024. The Euro-denominated distribution will be paid in Canadian dollars based on the exchange rate on the date of payment (estimated C$0.01468 per Unit and Class B LP Unit). Registered Unitholders will be provided with an option to elect to receive such distribution in Euros rather than Canadian dollars. If no such election is made, registered Unitholders will...

Predictive Oncology Reports First Quarter 2024 Financial Results and Provides Business Update

Written by Customer Service on May 15, 2024. Posted in Public Companies.

Company to host investor call and webcast today, May 15th, at 8:30am EDT PITTSBURGH, May 15, 2024 (GLOBE NEWSWIRE) — Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended March 31, 2024, and provided a corporate update. The company reported a net loss of approximately $4.2 million on total revenue of approximately $0.4 million for the quarter. Q1 2024 and Recent Highlights: Announced that an abstract detailing results of the recent study that Predictive Oncology completed in collaboration with UPMC Magee-Womens Hospital in Pittsburgh,...

Plug to Revolutionize Middle-Mile Delivery with Class 6 Fuel Cell Electric Truck Integration

Written by Customer Service on May 15, 2024. Posted in Public Companies.

LATHAM, N.Y., May 15, 2024 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in hydrogen solutions for the green hydrogen economy, has announced its latest innovation: the integration of a Class 6, medium-duty fuel cell electric truck. The integration involves a commercial Class 6 chassis cab with an industry proven electric propulsion system powered by Plug’s cutting-edge ProGen fuel cell technology and seamlessly integrated with an industry proven electric propulsion system. Fuel Cell Electric Vehicles (FCEVs) are powered by hydrogen and are more efficient than conventional internal combustion engine vehicles. Plug’s ProGen technology generates no harmful tailpipe emissions, emitting only water vapor and warm air. Designed specifically for middle-mile deliveries, this vehicle is engineered for unprecedented...

Sportradar Reports First Quarter 2024 Financial and Operating Results

Written by Customer Service on May 15, 2024. Posted in Public Companies.

Achieved Record Revenue of €266 Million, Up 28% and Grew Adjusted EBITDA 29% Raising 2024 Outlook for Revenue and Adjusted EBITDA Commencing Purchases Under Previously Announced Share Repurchase Program New CFO and Chief Technology & Chief AI Officer Join Sportradar Leadership Team ST. GALLEN, Switzerland, May 15, 2024 (GLOBE NEWSWIRE) — Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology company focused on creating immersive experiences for sports fans and bettors, today announced financial results for its first quarter ended March 31, 2024. Carsten Koerl, Chief Executive Officer of Sportradar, said: “Fiscal 2024 is off to a great start, building on the strong momentum and progress we made last year. This quarter, we saw broad-based strength across our product portfolio including...

OTC Markets Group Welcomes Butler National Corporation to OTCQX

Written by Customer Service on May 15, 2024. Posted in Public Companies.

NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Butler National Corporation (OTCQX: BUKS), a company that operates in the Aerospace and Professional Services industries, has qualified to trade on the OTCQX® Best Market. Butler National Corporation upgraded to OTCQX from the OTCQB® Venture Market. Butler National Corporation begins trading today on OTCQX under the symbol “BUKS.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. The OTCQX Market provides investors with a premium U.S. public market to research and trade the shares of investor-focused companies. Graduating to the OTCQX Market marks an important milestone for companies,...

Venus Concept Announces First Quarter of Fiscal Year 2024 Financial Results

Written by Customer Service on May 15, 2024. Posted in Public Companies.

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2024. First Quarter 2024 Summary & Recent Progress: Company continues to execute against Transformational Plan Cash used in operations of $2.9 million, down 51% year-over-year from $5.9 million Cash system revenue in first quarter 2024 represented approximately 75% of total systems and subscriptions revenue, compared to 66% in the prior year period Total revenue of $17.5 million, down 15% year-over-year but exceeded first quarter estimate of at least $16.5 million by 6% or $1.0 million. On April 3, 2024, the Company announced that it received Therapeutic Goods Administration (TGA) clearance in Australia...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice